BioAtlantis Ltd

BioAtlantis Ltd. is a biotechnology company working to provide solutions to problems caused by stresses in plants, animals and humans. These problems arise due to a range of factors and impact significantly upon productivity in agriculture and affect human and animal health. Agricultural systems are particularly affected by stresses associated with extreme weather or climatic conditions such as drought and salinity. Crops can also suffer from stress in soils with low organic matter content or pathogenic infestation as mediated, for example, by fungi and/or nematodes.

Company details

Clash Industrial Estate, , Tralee , Co. Kerry Ireland

Locations Served

Business Type:
Industry Type:
Market Focus:
Globally (various continents)

This company also provides solutions for agricultural applications.
Please, visit their profile in for more info.

BioAtlantis Ltd. was founded in 2004 and is located in Tralee, County Kerry, Ireland. The company was founded with the objective of identifying solutions to problems caused by stresses which impact upon biological processes in plants, animals and humans.

Since then, BioAtlantis has put in place the foundations to be a successful high-growth company. These foundations include a large body of scientific data and the filing of a number of patents. A fully automated extraction facility has been commissioned together with approval licenses. BioAtlantis is the first company in the British Isles to be granted a mechanical harvesting license for specific species of seaweed, which are sources of key bio actives.

A range of products including Super Fifty® 0-0-8, Alga 95®, Ecolicitor® and Nematec® have been developed for the plant strengthener sector to alleviate some of the problems caused by biotic and abiotic stresses. These products have been intensively trialed in research institutes which include the Applied Food and Bioscience Institute, Belfast, Northern Ireland (AFBI) and University College Cork, Ireland (UCC). The effectiveness of these products has also been verified through an intensive field trial process taking place in several countries. These products are registered for sale in many countries worldwide including Brazil, South Korea, Vietnam, Turkey and USA.

GutCare™ is our proprietary technology platform on gut health, performance and immunity in the monogastric animal. It has been developed over the last eight years in conjunction with the School of Science and Veterinary Medicine in University College Dublin, Ireland. State-of-the-art techniques have been used to develop this technology both in laboratory and on field-trial settings with effectiveness being determined over a broad range of key parameters including performance, immunity and maternal transfer and pathology.

The intensive production of monogastric animals also presents considerable challenges in agriculture, especially in regions such as Europe where in-feed growth promoting antibiotics have been banned since 2006. This has created immense challenges within this sector as viable alternatives to banned growth-promoters are not available.
BioAtlantis, in collaboration with its academic partners has amassed a significant body of scientific data during the last eight years, which has culminated in effective solutions to these problems. Market entry has been delayed in order to verify the robustness of the solution and we are now ready to launch the GutCare™ range.

Human health is also impacted upon by stresses which negatively affect biological processes. Such problems are being increasingly attributed to unhealthy dietary and lifestyle practices, along with a multitude of other underlying biological factors which are currently being elucidated. BioAtlantis in conjunction with its academic partners has identified solutions to a number of these problems. We now wish to join with suitable channel partners to introduce this technology and our solutions to the market place.

Digestica® has been developed for the human market and offers potential solutions to those suffering from gastrointestinal health problems and autoimmune issues.  Publications describing the effectiveness of this technology in human trials are soon to be published. The focus of the company now is to bring these solutions to the market in conjunction with appropriately qualified channel partners.